Results show the regimen of epcoritamab plus R-ICE could serve most patients as a bridge to either autologous stem cell ...

Tabelecleucel shows promising efficacy in treating EBV-positive PTLD, offering hope for patients resistant to previous ...

Epkinly (epcoritamab) is a subcutaneously delivered CD3×CD20 BiTE that secured FDA accelerated approval in 2023 for r/r DLBCL.

The BM12 CAST trial, a major clinical trial led by the Australasian Leukaemia & Lymphoma Group (ALLG) across New Zealand and Australian hospitals, will transform global blood stem cell transplant ...

By the end of the 4-0 loss to the Atlanta Braves in the opener of a four-game series, his arm was in a splint, and he was preparing for a flight back to Cincinnati Tuesday morning for surgery.

Last fall, the 29-year-old came to the Hospital of the University of Pennsylvania from his home in Switzerland for a rare ...

Rates of grade III/IV acute GVHD at 3 months were 3% with cyclophosphamide-cyclosporin prophylaxis and 10% with standard prophylaxis, reported David Curtis, MBBS, PhD, of Alfred H ...

Two posters presented at the 2025 European Hematology Association Congress support combination therapy with daratumumab, ...